Cost-utility of siltuximab injection for idiopathic multicentric Castleman disease (iMCD) in China

doi:10.5246/jcps.2023.10.068

Journal of Chinese Pharmaceutical Sciences ›› 2023, Vol. 32 ›› Issue (10): 842-851.DOI: 10.5246/jcps.2023.10.068

• Drug administration and clinical pharmacy column • Previous Articles Next Articles

Cost-utility of siltuximab injection for idiopathic multicentric Castleman disease (iMCD) in China

Jun Ma¹, Liangyu Ni², Qiyun Zhu³, Zhao Yang⁴^,^*(), Bin Jiang⁵^,^*()

1 Peking University Third Hospital, Beijing 100191, China
2 Peking University Health Science Center, Beijing 100191, China
3 University of California San Diego, San Diego 92093, USA
4 Peking University First Hospital, Beijing 100034, China
5 Department of Administrative and Clinical Pharmacy, Peking University School of Pharmaceutical Sciences, Beijing 100191, China

Received:2023-05-12 Revised:2023-06-01 Accepted:2023-06-14 Online:2023-11-04 Published:2023-11-04
Contact: Zhao Yang, Bin Jiang

Abstract

Abstract:

Siltuximab is an innovative drug used to treat idiopathic multicentric Castleman disease (iMCD), a rare condition. Clinical trials have demonstrated its efficacy and safety. However, there is limited research on the economic evaluation of siltuximab. Therefore, using a partition survival model, we aimed to evaluate the average treatment cost and health outcomes for Chinese patients with iMCD in the siltuximab group compared to the placebo group based on existing clinical and published data. We also conducted price threshold analysis, incremental cost-utility analysis, and sensitivity analysis. The results revealed that compared to the placebo group, the siltuximab group showed an increase of 6.31 life-years (LYs) and 5.09 quality-adjusted life-years (QALYs). At a willingness-to-pay (WTP) threshold of 242 928 yuan/QALY, the maximum price threshold for siltuximab compared to the placebo group was 8921.47 yuan per bottle (400 mg). Therefore, as a first-line treatment for iMCD, siltuximab demonstrated superior health outcomes compared to placebo.

Key words: Siltuximab, Idiopathic multicentric Castleman disease, Cost-utility, Partitioned survival model

Supporting:

Jun Ma, Liangyu Ni, Qiyun Zhu, Zhao Yang, Bin Jiang. Cost-utility of siltuximab injection for idiopathic multicentric Castleman disease (iMCD) in China[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(10): 842-851.

Figures/Tables 10

Table 1. AIC and BIC of standard parameter model fitting K-M curve.

Table 2. Health status utility.

Table 3. Health outcome analysis.

Table 4. Health outcome analysis.

Table 5. Incremental cost-utility analysis results.

References 17

[1]	Dispenzieri, A.; Armitage, J.O.; Loe, M.J.; Geyer, S.M.; Allred, J.; Camoriano, J.K.; Menke, D.M.; Weisenburger, D.D.; Ristow, K.; Dogan, A.; Habermann, T.M. The clinical spectrum of Castleman’s disease. Am. J. Hematol. 2012, 87, 997–1002.
[2]	Dispenzieri, A.; Fajgenbaum, D.C. Overview of castleman disease. Blood 2020, 135, 1353–1364.
[3]	Fajgenbaum, D.C.; Uldrick, T.S.; Bagg, A.; Frank, D.; Wu, D.; Srkalovic, G.; Simpson, D.; Liu, A.Y.; Menke, D.; Chandrakasan, S.; Lechowicz, M.J.; Wong, R.S.M.; Pierson, S.; Paessler, M.; Rossi, J.F.; Ide, M.; Ruth, J.; Croglio, M.; Suarez, A.; Krymskaya, V.; Chadburn, A.; Colleoni, G.; Nasta, S.; Jayanthan, R.; Nabel, C.S.; Casper, C.; Dispenzieri, A.; Fosså, A.; Kelleher, D.; Kurzrock, R.; Voorhees, P.; Dogan, A.; Yoshizaki, K.; van Rhee, F.; Oksenhendler, E.; Jaffe, E.S.; Elenitoba-Johnson, K.S.J.; Lim, M.S. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017, 129, 1646–1657.
[4]	Liu, A.Y.; Nabel, C.S.; Finkelman, B.S.; Ruth, J.R.; Kurzrock, R.; van Rhee, F.; Krymskaya, V.P.; Kelleher, D.; Rubenstein, A.H.; Fajgenbaum, D.C. Idiopathic multicentric Castleman’s disease: a systematic literature review. Lancet Haematol. 2016, 3, e163–e175.
[5]	Mukherjee, S.; Martin, R.; Sande, B.; Paige, J.S.; Fajgenbaum, D.C. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6–directed therapy. Blood Adv. 2022, 6, 359–367.
[6]	Dong, Y.J.; Wang, M.Y.; Nong, L.; Wang, L.H.; Cen, X.N.; Liu, W.; Zhu, S.N.; Sun, Y.H.; Liang, Z.Y.; Li, Y.; Ou, J.P.; Qiu, Z.X.; Ren, H.Y. Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor. Br. J. Haematol. 2015, 169, 834–842.
[7]	Yu, L.; Tu, M.F.; Cortes, J.; Xu-Monette, Z.Y.; Miranda, R.N.; Zhang, J.; Orlowski, R.Z.; Neelapu, S.; Boddu, P.C.; Akosile, M.A.; Uldrick, T.S.; Yarchoan, R.; Medeiros, L.J.; Li, Y.; Fajgenbaum, D.C.; Young, K.H. Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease. Blood. 2017, 129, 1658–1668.
[8]	Zhang, X.Y.; Rao, H.L.; Xu, X.L.; Li, Z.H.; Liao, B.; Wu, H.M.; Li, M.; Tong, X.Z.; Li, J.; Cai, Q.Q. Clinical characteristics and outcomes of Castleman disease: a multicenter study of 185 Chinese patients. Cancer Sci. 2018, 109, 199–206.
[9]	Abramson, J.S. Diagnosis and management of castleman disease. J. Natl. Compr. Canc. Netw. 2019, 17, 1417–1419.
[10]	Ferrario, A.; Merli, M.; Basilico, C.; Maffioli, M.; Passamonti, F. Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma. Expert Opin. Investig. Drugs. 2017, 26, 367–373.
[11]	Markham, A.; Patel, T. Siltuximab: first global approval. Drugs. 2014, 74, 1147–1152.
[12]	Sitenga, J.; Aird, G.; Ahmed, A.; Silberstein, P.T. Impact of siltuximab on patient-related outcomes in multicentric Castleman’s disease. Patient Relat. Outcome Meas. 2018, 9, 35–41.
[13]	van Rhee, F.; Wong, R.S.; Munshi, N.; Rossi, J.F.; Ke, X.Y.; Fosså, A.; Simpson, D.; Capra, M.; Liu, T.; Hsieh, R.K.; Goh, Y.T.; Zhu, J.; Cho, S.G.; Ren, H.Y.; Cavet, J.; Bandekar, R.; Rothman, M.; Puchalski, T.A.; Reddy, M.; van de Velde, H.; Casper, C. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014, 15, 966–974.
[14]	Lyseng-Williamson, K.A. Siltuximab: a review in idiopathic (human herpesvirus-8-negative) multicentric castleman disease. BioDrugs. 2015, 29, 399–406.
[15]	van Rhee, F.; Casper, C.; Voorhees, P.M.; Fayad, L.E.; Gibson, D.; Kanhai, K.R.; Kurzrock, R. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. Lancet Haematol. 2020, 7, e209–e217.
[16]	It’s from the the Pharmaceutical Benefits Scheme (PBS). The document was released in November 2021 (https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2021-11/files/siltuximab-psd-nov-2021.pdf).
[17]	It’s from the Canada’s Drug and Health Technology Agency (CADTH). pCODR Final Economic Guidance Report–Siltuximab (Sylvant) for Multicentric Castleman’s Disease was released in June 2015 (https://www.cadth.ca/sites/default/files/pcodr/pcodr_siltuximab_sylvant_mcd_ fn_egr.pdf).

Cost-utility of siltuximab injection for idiopathic multicentric Castleman disease (iMCD) in China

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 10

References 17

Related Articles 1

Recommended Articles

Metrics

Comments